HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania

2010 ◽  
Vol 15 (7) ◽  
pp. 1003-1009 ◽  
Author(s):  
Asgeir Johannessen ◽  
Mona Holberg-Petersen ◽  
Gunilla Lövgaarden ◽  
Ezra Naman ◽  
Vidar Ormaasen ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Dried Blood Spots ◽  
Resistance Testing ◽  
Blood Spots ◽  
Drug Resistance Testing ◽  
Rural Tanzania ◽  
Hiv Type 1

scholarly journals HIV-2 Drug Resistance Genotyping from Dried Blood Spots

2020 ◽  
Vol 59 (1) ◽  
pp. e02303-20
Author(s):  
Dana N. Raugi ◽  
Robert S. Nixon ◽  
Sally Leong ◽  
Khadim Faye ◽  
Jean Phillipe Diatta ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Viral Load ◽  
Plasma Viral Load ◽  
Mononuclear Cells ◽  
Dried Blood Spots ◽  
Antiretroviral Drugs ◽  
Resistance Testing ◽  
Peripheral Blood Mononuclear ◽  
Blood Spots ◽  
Drug Resistance Testing

ABSTRACTThe treatment of HIV-2 in resource-limited settings (RLS) is complicated by the limited availability of HIV-2-active antiretroviral drugs and inadequate access to HIV-2 viral load and drug resistance testing. Dried blood spots (DBS)-based drug resistance testing, widely studied for HIV-1, has not been reported for HIV-2 and could present an opportunity to improve care for HIV-2-infected individuals. We selected 150 DBS specimens from ongoing studies of antiretroviral therapy (ART) for HIV-2 infection in Senegal and subjected them to genotypic drug resistance testing. Total nucleic acid was extracted from DBS, reverse transcribed, PCR amplified, and analyzed by population-based Sanger sequencing, and major drug resistance-associated mutations (RAM) were identified. Parallel samples from plasma and peripheral blood mononuclear cells (PBMC) were also genotyped. We obtained 58 protease/reverse transcriptase genotypes. Plasma viral load was significantly correlated with genotyping success (P < 0.001); DBS samples with corresponding plasma viral load >250 copies/ml had a success rate of 86.8%. In paired DBS-plasma genotypes, 83.8% of RAM found in plasma were also found in DBS, and replicate DBS genotyping revealed that a single test detected 86.7% of known RAM. These findings demonstrate that DBS-based genotypic drug resistance testing for HIV-2 is feasible and can be deployed in RLS with limited infrastructure.

Drug Resistance Testing Provides Evidence of the Globalization of HIV Type 1: A New Circulating Recombinant Form

2004 ◽  
Vol 20 (8) ◽  
pp. 885-888 ◽  
Author(s):  
Manuel Gómez-Carrillo ◽  
Jorge F. Quarleri ◽  
Andrea E. Rubio ◽  
Mauricio G. Carobene ◽  
Darío Dilernia ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Recombinant Form ◽  
Resistance Testing ◽  
Drug Resistance Testing ◽  
Hiv Type 1

Discrepancies in Assignment of Subtype/Recombinant Forms by Genotyping Programs for HIV Type 1 Drug Resistance Testing May Falsely Predict Superinfection

2008 ◽  
Vol 24 (7) ◽  
pp. 995-1002 ◽  
Author(s):  
Michel Ntemgwa ◽  
M. John Gill ◽  
Bluma G. Brenner ◽  
Daniela Moisi ◽  
Mark A. Wainberg
Keyword(s):  
Drug Resistance ◽  
Resistance Testing ◽  
Drug Resistance Testing ◽  
Hiv Type 1

scholarly journals HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya

2014 ◽  
Vol 7 (1) ◽  
pp. 890 ◽  
Author(s):  
Peter Koigi ◽  
Musa Ngayo ◽  
Samoel Khamadi ◽  
Caroline Ngugi ◽  
Anthony Nyamache
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Second Line ◽  
Resistance Patterns ◽  
Hiv Type 1 ◽  
Second Line Antiretroviral Therapy
Sign in / Sign up

Export Citation Format

Share Document